← All indications
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Drugs by status
Approved for this indication (24)
- memantine
- l-alpha-glycerophosphocholine
- aducanumab
- flortaucipir
- galantamine
- astaxanthin
- phosphatidylcholine
- iofetamine
- LECANEMAB
- omega-3 fatty acids
- homotaurine
- tacrine
- donepezil
- donanemab
- rivastigmine
- fulvic acid
- florbetaben F-18
- idebenone
- florbetapir
- flutemetamol F-18
- huperzine a
- cyclomandol
- dihydroergocornine mesylate
- sodium oligo-mannurarate
Phase 4 trials (46)
- pravastatin
- valproic acid
- piracetam
- pittsburgh compound b
- gabapentin
- hydrocodone
- aripiprazole
- atorvastatin
- ramipril
- olanzapine
- carvedilol
- lacosamide
- sodium oxybate
- amphetamine
- nicotergoline
- levetiracetam
- sertraline
- propofol
- simvastatin
- acetaminophen
- escitalopram
- l-histidine
- risperidone
- krill oil
- tricaprylyl glycerol
- ibuprofen
- daridorexant
- yinhsing
- acetylcarnitine
- cenegermin-bkbj
- +16 more
Phase 3 trials (125)
- verubecestat
- masupirdine
- piromelatine
- iloperidone
- ar1001
- atuzaginstat
- nabilone
- tributyrin
- diphenhydramine
- multivitamins
- sitagliptin
- bpdo-1603
- estradiol
- amlodipine
- xaliproden hydrochloride
- collagen
- octohydroaminoacridine
- fentanyl
- thalidomide
- raloxifene
- estrogen
- Hydromethylthionine
- prednisone
- alz-801
- gv 1001
- masitinib
- vitamin d3
- t3d-959
- pseudoephedrine
- blarcamesine
- +95 more
Phase 2 trials (287)
- ntrx-07-sdd
- 18f-pbr06
- vi-1121
- chf5074
- brexanolone
- avagacestat
- canakinumab
- vgh-ad1
- mk-2214
- florbenazine
- abt-288
- autologous regulatory t cells
- amdx2011p
- ei1071
- aph-1105
- evp-0962
- gsk4527226
- dapagliflozin
- empagliflozin
- trx0014
- pimavanserin
- Melia toosendan
- senicapoc
- Mevidalen
- traneurocin
- oleoylestrone
- lithium
- fasudil
- mc2-25
- azd4694
- +257 more
Phase 1 trials (200)
Other trials (52)
- sulforaphane
- blueberry
- zt-1
- allogeneic blood cells
- lidocaine
- soybean
- prilocaine
- leucine
- gonadorelin
- beta-glucans
- bombyx mori fiber
- methylreboxetine
- eicosapentanoic acid
- butylphthalide
- i-123-5-ia85380
- glycerin
- genistein
- probiotic k10
- sevoflurane
- morus nigra
- amisulpride
- ezetimibe
- chromium trichloride
- cyclodextrin
- tannic acid
- apolipoprotein
- nitrogen
- lactobacillus reuteri
- carpalatine
- black raspberry
- +22 more
Organizations
Organization Involved with Phase 4 Indications (107)
- Abbott
- University of Rochester
- Taiwanese Society of Psychiatry
- Alzheimer's Society
- University of Heidelberg
- Daewoong Pharmaceutical Co. LTD.
- Hospital Universitario Arnau de Vilanova de Lleida
- Queen Elizabeth Hospital NHS Foundation Trust
- Yuhan Pharmaceutical Company
- Zhejiang University
- University of Ulsan
- University of London
- Harvard University
- Catholic University of Korea
- University of California, San Diego
- Jiao Tong University
- Ono Pharmaceuticals
- University of Toronto
- Fisher Center for Alzheimer's Research Foundation
- Novartis
- University of Manchester
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of Copenhagen
- University of Hamburg
- Associacao Fundo de Incentivo a Psicofarmcologia
- Free University of Berlin
- University of Wisconsin
- American Health Assistance Foundation
- Emory University
- University of Cincinnati
- +77 more
Organization Involved with Phase 3 Indications (137)
- AB Science
- Weston Brain Institute
- Hamilton Health Sciences Corporation
- Alzheimer’s Drug Discovery Foundation
- Netherlands Brain Foundation
- Biohaven Pharmaceuticals Inc.
- University of Barcelona
- Medical University of South Carolina
- Dong-A University
- Michigan State University
- National Center for Complementary and Integrative Health (NCCIH)
- McMaster University
- Saarland University
- Wake Forest University
- Groupement Interrégional de Recherche Clinique et d'Innovation Est
- Technical University of Dresden
- Myrexis Inc.
- University of Vermont
- France Alzheimer
- University of Lille
- Navidea Biopharmaceuticals
- Netherlands Alzheimer Foundation
- Alzheimer Europe
- Western Psychiatric Institute & Clinic
- Government of France
- Office of Dietary Supplements (ODS)
- University of California, Irvine
- National Taiwan University
- University of Southern California
- Mitsubishi Tanabe
- +107 more
Organization Involved with Phase 2 Indications (232)
- Eastern Virginia Medical School
- Genentech
- Neurim Pharmaceuticals Ltd.
- Aprinoia Therapeutics Inc.
- Corcept Therapeutics
- American College of Radiology
- Invicro
- IlDong Pharmaceutical Co Ltd
- A2 Healthcare Taiwan Corporation
- China Academy of Chinese Medical Sciences
- Sun Yat-Sen University
- Alterity Therapeutics
- Saegis Pharmaceuticals
- Octapharma
- Avraham Pharmaceuticals Ltd
- Pharmaceutical Research Associates, Inc. (PRA)
- Southern Illinois University
- West Virginia University
- Virginia Commonwealth University
- NeuroActiva
- acromion GmbH
- Elan Pharmaceuticals
- California Clinical Trials
- National Cheng Kung University
- Teva
- Guangzhou Medical University
- The Memory Enhancement Center of America, Inc.
- T3D Therapeutics, Inc.
- University of Utah
- University of Virginia
- +202 more
Organization Involved with Phase 1 Indications (92)
- Comprehensive Clinical Development, Inc.
- University of Kentucky
- St. Louis Clinical Trials, LC
- Ceregene
- QPS
- Molecular NeuroImaging
- Forschungszentrum Jülich
- Celerion
- Denali Therapeutics Inc.
- Yeshiva University
- Government of Sweden
- High Point Pharmaceuticals, LLC.
- Rodin Therapeutics
- IDT Australia Ltd.
- ReXceptor, Inc.
- Corium International Inc.
- Allergan
- reMYND
- Paul H. Wand M.D., P.A.
- Northern Ontario School of Medicine
- Northwestern University
- European Commission
- University of Rhode Island
- Iberica Co. Ltd.
- Fundación Teófilo Hernando, Spain
- WCCT Global
- Triskelion, The Netherlands
- Loma Linda University
- German Center for Neurodegenerative Diseases (DZNE)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- +62 more
Organization Involved with Other Experimental Indications (43)
- University of Montpellier
- University of Paris
- Metabolic Therapy Inc.
- University of Franche-Comté
- Debiopharm
- International Atomic Energy Agency
- University of Reims
- Tianjin Medical University
- Tsinghua University
- Auburn University
- University of Sherbrooke
- University of Lyon
- University of Versailles
- Kerwin Research Center
- Fondation Vitae
- Cyclotherapeutics
- Zhitong Biopharma CO.,LTD
- Aarhus University
- Aix-University of Marseille
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Iceland
- Kuopio University Hospital
- Mentis Cura
- Magceutics, Inc.
- Shanghai University of Traditional Chinese Medicine
- Pasqual Maragall Foundation
- Kowa
- University of Valencia
- Fudan University
- Regenstrief Institute
- +13 more